The Matrix Protein of Nipah Virus Targets the E3-Ubiquitin Ligase TRIM6 to Inhibit the IKKε Kinase-Mediated Type-I IFN Antiviral Response

PLoS Pathogens

Volumn 12, Issue 9, 2016, Pages

  Bharaj, Preeti ^a   Wang, Yao E ^b   Dawes, Brian E ^a   Yun, Tatyana E ^a   Park, Arnold ^b   Yen, Benjamin ^b   Basler, Christopher F ^b,c   Freiberg, Alexander N ^a   Lee, Benhur ^b   Rajsbaum, Ricardo ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c GEORGIA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHAN1 INTERFERON; BETA1 INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; I KAPPA B KINASE EPSILON; INTERLEUKIN 12P40; INTERLEUKIN 4; LENTIVIRUS VECTOR; MATRIX PROTEIN; NIPAH VIRUS MATRIX PROTEIN; POLYUBIQUITIN; RETINOIC ACID INDUCIBLE PROTEIN I; TRIPARTITE MOTIF PROTEIN 5; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG; I KAPPA B KINASE; INTERFERON; TRIM6 PROTEIN, HUMAN; TRIPARTITE MOTIF PROTEIN; UBIQUITIN PROTEIN LIGASE; VIRAL PROTEIN;

ANIMAL CELL; ANTIVIRAL RESISTANCE; ARTICLE; CONTROLLED STUDY; FLOW CYTOMETRY; GENE SILENCING; GENE TARGETING; GHANA; HENDRA VIRUS INFECTION; HUMAN; HUMAN CELL; IMAGE ANALYSIS; IMMUNE RESPONSE; IMMUNOFLUORESCENCE MICROSCOPY; IMMUNOPRECIPITATION; INNATE IMMUNITY; NIPAH VIRUS; NONHUMAN; PROTEIN DEGRADATION; REAL TIME POLYMERASE CHAIN REACTION; VIRUS ASSEMBLY; VIRUS RELEASE; WESTERN BLOTTING; A-549 CELL LINE; ANIMAL; CHLOROCEBUS AETHIOPS; GENETICS; HELA CELL LINE; HENIPAVIRUS INFECTION; IMMUNE EVASION; IMMUNOLOGY; PROTEIN MULTIMERIZATION; UBIQUITINATION; VERO CELL LINE;

A549 CELLS; ANIMALS; CERCOPITHECUS AETHIOPS; HELA CELLS; HENIPAVIRUS INFECTIONS; HUMANS; I-KAPPA B KINASE; IMMUNE EVASION; IMMUNITY, INNATE; INTERFERON TYPE I; NIPAH VIRUS; POLYUBIQUITIN; PROTEIN MULTIMERIZATION; TRIPARTITE MOTIF PROTEINS; UBIQUITIN-PROTEIN LIGASES; UBIQUITINATION; VERO CELLS; VIRAL PROTEINS;

EID: 84989917334     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1005880     Document Type: Article

References (59)

1. Medzhitov R, Preston-Hurlburt P, Janeway CA, JrA human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature. 1997;388(6640):394–7.
2. Meylan E, Tschopp J, Karin M, Intracellular pattern recognition receptors in the host response. Nature. 2006;442(7098):39–44. doi: 10.1038/nature0494616823444.
3. Gitlin L, Barchet W, Gilfillan S, Cella M, Beutler B, Flavell RA, et al. Essential role of mda-5 in type I IFN responses to polyriboinosinic:polyribocytidylic acid and encephalomyocarditis picornavirus. Proc Natl Acad Sci U S A. 2006;103(22):8459–64. doi: 10.1073/pnas.060308210316714379; PubMed Central PMCID: PMCPMC1464000.
4. Yoneyama M, Kikuchi M, Natsukawa T, Shinobu N, Imaizumi T, Miyagishi M, et al. The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nat Immunol. 2004;5(7):730–7. doi: 10.1038/ni108715208624.
5. Kawai T, Takahashi K, Sato S, Coban C, Kumar H, Kato H, et al. IPS-1, an adaptor triggering RIG-I- and Mda5-mediated type I interferon induction. Nat Immunol. 2005;6(10):981–8. doi: 10.1038/ni124316127453.
6. Yamamoto M, Sato S, Hemmi H, Hoshino K, Kaisho T, Sanjo H, et al. Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway. Science. 2003;301(5633):640–3. doi: 10.1126/science.108726212855817.
7. Hemmi H, Takeuchi O, Sato S, Yamamoto M, Kaisho T, Sanjo H, et al. The roles of two IkappaB kinase-related kinases in lipopolysaccharide and double stranded RNA signaling and viral infection. J Exp Med. 2004;199(12):1641–50. doi: 10.1084/jem.2004052015210742; PubMed Central PMCID: PMCPMC2212809.
8. Sharma S, tenOever BR, Grandvaux N, Zhou GP, Lin R, Hiscott J, Triggering the interferon antiviral response through an IKK-related pathway. Science. 2003;300(5622):1148–51. doi: 10.1126/science.108131512702806.
9. Rahman MM, McFadden G, Modulation of NF-kappaB signalling by microbial pathogens. Nat Rev Microbiol. 2011;9(4):291–306. doi: 10.1038/nrmicro253921383764; PubMed Central PMCID: PMCPMC3611960.
10. Vallabhapurapu S, Karin M, Regulation and function of NF-kappaB transcription factors in the immune system. Annu Rev Immunol. 2009;27:693–733. doi: 10.1146/annurev.immunol.021908.13264119302050.
11. Platanias LC, Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat Rev Immunol. 2005;5(5):375–86. doi: 10.1038/nri160415864272.
12. Ng SL, Friedman BA, Schmid S, Gertz J, Myers RM, Tenoever BR, et al. IkappaB kinase epsilon (IKK(epsilon)) regulates the balance between type I and type II interferon responses. Proc Natl Acad Sci U S A. 2011;108(52):21170–5. doi: 10.1073/pnas.111913710922171011; PubMed Central PMCID: PMCPMC3248534.
13. Rajsbaum R, Versteeg GA, Schmid S, Maestre AM, Belicha-Villanueva A, Martinez-Romero C, et al. Unanchored K48-linked polyubiquitin synthesized by the E3-ubiquitin ligase TRIM6 stimulates the interferon-IKKepsilon kinase-mediated antiviral response. Immunity. 2014;40(6):880–95. doi: 10.1016/j.immuni.2014.04.01824882218; PubMed Central PMCID: PMCPMC4114019.
14. Tenoever BR, Ng SL, Chua MA, McWhirter SM, Garcia-Sastre A, Maniatis T, Multiple functions of the IKK-related kinase IKKepsilon in interferon-mediated antiviral immunity. Science. 2007;315(5816):1274–8.
15. Rajsbaum R, Garcia-Sastre A, Viral evasion mechanisms of early antiviral responses involving regulation of ubiquitin pathways. Trends Microbiol. 2013;21(8):421–9.
16. Rajsbaum R, Garcia-Sastre A, Versteeg GA, TRIMmunity: the roles of the TRIM E3-ubiquitin ligase family in innate antiviral immunity. J Mol Biol. 2014;426(6):1265–84. doi: 10.1016/j.jmb.2013.12.00524333484; PubMed Central PMCID: PMCPMC3945521.
17. Rajsbaum R, Stoye JP, O'Garra A, Type I interferon-dependent and -independent expression of tripartite motif proteins in immune cells. Eur J Immunol. 2008;38(3):619–30.
18. Uchil PD, Hinz A, Siegel S, Coenen-Stass A, Pertel T, Luban J, et al. TRIM protein-mediated regulation of inflammatory and innate immune signaling and its association with antiretroviral activity. J Virol. 2013;87(1):257–72. doi: 10.1128/JVI.01804-1223077300; PubMed Central PMCID: PMCPMC3536418.
19. Versteeg GA, Benke S, Garcia-Sastre A, Rajsbaum R, InTRIMsic immunity: Positive and negative regulation of immune signaling by tripartite motif proteins. Cytokine Growth Factor Rev. 2014;25(5):563–76. doi: 10.1016/j.cytogfr.2014.08.00125172371.
20. Versteeg GA, Rajsbaum R, Sanchez-Aparicio MT, Maestre AM, Valdiviezo J, Shi M, et al. The E3-ligase TRIM family of proteins regulates signaling pathways triggered by innate immune pattern-recognition receptors. Immunity. 2013;38(2):384–98.
21. Kolakofsky D, Roux L, Garcin D, Ruigrok RW, Paramyxovirus mRNA editing, the "rule of six" and error catastrophe: a hypothesis. J Gen Virol. 2005;86(Pt 7):1869–77.
22. Didcock L, Young DF, Goodbourn S, Randall RE, The V protein of simian virus 5 inhibits interferon signalling by targeting STAT1 for proteasome-mediated degradation. J Virol. 1999;73(12):9928–33. 10559305; PubMed Central PMCID: PMCPMC113042.
23. Parisien JP, Lau JF, Rodriguez JJ, Sullivan BM, Moscona A, Parks GD, et al. The V protein of human parainfluenza virus 2 antagonizes type I interferon responses by destabilizing signal transducer and activator of transcription 2. Virology. 2001;283(2):230–9. doi: 10.1006/viro.2001.085611336548.
24. Rodriguez JJ, Parisien JP, Horvath CM, Nipah virus V protein evades alpha and gamma interferons by preventing STAT1 and STAT2 activation and nuclear accumulation. J Virol. 2002;76(22):11476–83. 12388709; PubMed Central PMCID: PMCPMC136769.
25. Rodriguez JJ, Wang LF, Horvath CM, Hendra virus V protein inhibits interferon signaling by preventing STAT1 and STAT2 nuclear accumulation. J Virol. 2003;77(21):11842–5. 14557668; PubMed Central PMCID: PMCPMC229371.
26. Palosaari H, Parisien JP, Rodriguez JJ, Ulane CM, Horvath CM, STAT protein interference and suppression of cytokine signal transduction by measles virus V protein. J Virol. 2003;77(13):7635–44. 12805463; PubMed Central PMCID: PMCPMC164804.
27. Eaton BT, Broder CC, Middleton D, Wang LF, Hendra and Nipah viruses: different and dangerous. Nat Rev Microbiol. 2006;4(1):23–35.
28. Field H, Young P, Yob JM, Mills J, Hall L, Mackenzie J, The natural history of Hendra and Nipah viruses. Microbes Infect. 2001;3(4):307–14. 11334748.
29. Shaw ML, Garcia-Sastre A, Palese P, Basler CF, Nipah virus V and W proteins have a common STAT1-binding domain yet inhibit STAT1 activation from the cytoplasmic and nuclear compartments, respectively. J Virol. 2004;78(11):5633–41.
30. Andrejeva J, Childs KS, Young DF, Carlos TS, Stock N, Goodbourn S, et al. The V proteins of paramyxoviruses bind the IFN-inducible RNA helicase, mda-5, and inhibit its activation of the IFN-beta promoter. Proc Natl Acad Sci U S A. 2004;101(49):17264–9. doi: 10.1073/pnas.040763910115563593; PubMed Central PMCID: PMCPMC535396.
31. Schroder M, Baran M, Bowie AG, Viral targeting of DEAD box protein 3 reveals its role in TBK1/IKKepsilon-mediated IRF activation. EMBO J. 2008;27(15):2147–57. doi: 10.1038/emboj.2008.14318636090; PubMed Central PMCID: PMCPMC2516890.
32. Sen GC, Viruses and interferons. Annu Rev Microbiol. 2001;55:255–81. doi: 10.1146/annurev.micro.55.1.25511544356.
33. Shaw ML, Cardenas WB, Zamarin D, Palese P, Basler CF, Nuclear localization of the Nipah virus W protein allows for inhibition of both virus- and toll-like receptor 3-triggered signaling pathways. J Virol. 200579: 6078–6088. doi: 10.1128/JVI.79.10.6078-6088.200515857993; PubMed Central PMCID: PMC1091709.
34. Ciancanelli MJ, Volchkova VA, Shaw ML, Volchkov VE, Basler CF, Nipah virus sequesters inactive STAT1 in the nucleus via a P gene-encoded mechanism. J Virol. 2009;83(16):7828–41. doi: 10.1128/JVI.02610-0819515782; PubMed Central PMCID: PMCPMC2715789.
35. Virtue ER, Marsh GA, Baker ML, Wang LF, Interferon production and signaling pathways are antagonized during henipavirus infection of fruit bat cell lines. PLoS One. 2011;6(7):e22488. doi: 10.1371/journal.pone.002248821811620; PubMed Central PMCID: PMCPMC3139658.
36. Yoneda M, Guillaume V, Sato H, Fujita K, Georges-Courbot MC, Ikeda F, et al. The nonstructural proteins of Nipah virus play a key role in pathogenicity in experimentally infected animals. PLoS One. 2010;5(9):e12709. doi: 10.1371/journal.pone.001270920856799; PubMed Central PMCID: PMCPMC2939873.
37. Virtue ER, Marsh GA, Wang LF, Interferon signaling remains functional during henipavirus infection of human cell lines. J Virol. 2011;85(8):4031–4. doi: 10.1128/JVI.02412-1021289115; PubMed Central PMCID: PMCPMC3126122.
38. Wang YE, Park A, Lake M, Pentecost M, Torres B, Yun TE, et al. Ubiquitin-regulated nuclear-cytoplasmic trafficking of the Nipah virus matrix protein is important for viral budding. PLoS Pathog. 2010;6(11):e1001186. doi: 10.1371/journal.ppat.100118621085610; PubMed Central PMCID: PMCPMC2978725.
39. Pentecost M, Vashisht AA, Lester T, Voros T, Beaty SM, Park A, et al. Evidence for ubiquitin-regulated nuclear and subnuclear trafficking among Paramyxovirinae matrix proteins. PLoS Pathog. 2015;11(3):e1004739. doi: 10.1371/journal.ppat.100473925782006; PubMed Central PMCID: PMCPMC4363627.
40. Park MS, Shaw ML, Munoz-Jordan J, Cros JF, Nakaya T, Bouvier N, et al. Newcastle disease virus (NDV)-based assay demonstrates interferon-antagonist activity for the NDV V protein and the Nipah virus V, W, and C proteins. J Virol. 2003;77(2):1501–11. 12502864; PubMed Central PMCID: PMCPMC140815.
41. Mathieu C, Pohl C, Szecsi J, Trajkovic-Bodennec S, Devergnas S, Raoul H, et al. Nipah virus uses leukocytes for efficient dissemination within a host. J Virol. 2011;85(15):7863–71. doi: 10.1128/JVI.00549-1121593145; PubMed Central PMCID: PMCPMC3147937.
42. Basler CF, Wang X, Muhlberger E, Volchkov V, Paragas J, Klenk HD, et al. The Ebola virus VP35 protein functions as a type I IFN antagonist. Proc Natl Acad Sci U S A. 2000;97(22):12289–94. doi: 10.1073/pnas.22039829711027311; PubMed Central PMCID: PMCPMC17334.
43. Ramanan P, Shabman RS, Brown CS, Amarasinghe GK, Basler CF, Leung DW, Filoviral immune evasion mechanisms. Viruses. 2011;3(9):1634–49.
44. Yen B, Mulder LC, Martinez O, Basler CF, Molecular basis for ebolavirus VP35 suppression of human dendritic cell maturation. J Virol. 2014;88(21):12500–10. doi: 10.1128/JVI.02163-1425142601; PubMed Central PMCID: PMCPMC4248944.
45. Luthra P, Ramanan P, Mire CE, Weisend C, Tsuda Y, Yen B, et al. Mutual antagonism between the Ebola virus VP35 protein and the RIG-I activator PACT determines infection outcome. Cell Host Microbe. 2013;14(1):74–84. doi: 10.1016/j.chom.2013.06.01023870315; PubMed Central PMCID: PMCPMC3875338.
46. Seth RB, Sun L, Ea CK, Chen ZJ, Identification and characterization of MAVS, a mitochondrial antiviral signaling protein that activates NF-kappaB and IRF 3. Cell. 2005;122(5):669–82.
47. Drexler JF, Corman VM, Gloza-Rausch F, Seebens A, Annan A, Ipsen A, et al. Henipavirus RNA in African bats. PLoS One. 2009;4(7):e6367. doi: 10.1371/journal.pone.000636719636378; PubMed Central PMCID: PMCPMC2712088.
48. Pernet O, Schneider BS, Beaty SM, LeBreton M, Yun TE, Park A, et al. Evidence for henipavirus spillover into human populations in Africa. Nat Commun. 2014;5:5342. doi: 10.1038/ncomms634225405640; PubMed Central PMCID: PMCPMC4237230.
49. Lieu KG, Marsh GA, Wang LF, Netter HJ, The non-pathogenic Henipavirus Cedar paramyxovirus phosphoprotein has a compromised ability to target STAT1 and STAT2. Antiviral Res. 2015;124:69–76. doi: 10.1016/j.antiviral.2015.09.01726526590.
50. Marsh GA, de Jong C, Barr JA, Tachedjian M, Smith C, Middleton D, et al. Cedar virus: a novel Henipavirus isolated from Australian bats. PLoS Pathog. 2012;8(8):e1002836. doi: 10.1371/journal.ppat.100283622879820; PubMed Central PMCID: PMCPMC3410871.
51. Reymond A, Meroni G, Fantozzi A, Merla G, Cairo S, Luzi L, et al. The tripartite motif family identifies cell compartments. EMBO J. 2001;20(9):2140–51. doi: 10.1093/emboj/20.9.214011331580; PubMed Central PMCID: PMCPMC125245.
52. Dietzel E, Kolesnikova L, Sawatsky B, Heiner A, Weis M, Kobinger GP, et al. Nipah Virus Matrix Protein Influences Fusogenicity and Is Essential for Particle Infectivity and Stability. J Virol. 2015;90(5):2514–22. doi: 10.1128/JVI.02920-1526676785; PubMed Central PMCID: PMCPMC4810686.
53. Diaz-Griffero F, Li X, Javanbakht H, Song B, Welikala S, Stremlau M, et al. Rapid turnover and polyubiquitylation of the retroviral restriction factor TRIM5. Virology. 2006;349(2):300–15. doi: 10.1016/j.virol.2005.12.04016472833.
54. Li X, Song B, Xiang SH, Sodroski J, Functional interplay between the B-box 2 and the B30.2(SPRY) domains of TRIM5alpha. Virology. 2007;366(2):234–44. doi: 10.1016/j.virol.2007.04.02217543365; PubMed Central PMCID: PMCPMC2040257.
55. Han YH, Moon HJ, You BR, Park WH, The effect of MG132, a proteasome inhibitor on HeLa cells in relation to cell growth, reactive oxygen species and GSH. Oncol Rep. 2009;22(1):215–21. 19513526.
56. Dunmore BJ, Drake KM, Upton PD, Toshner MR, Aldred MA, Morrell NW, The lysosomal inhibitor, chloroquine, increases cell surface BMPR-II levels and restores BMP9 signalling in endothelial cells harbouring BMPR-II mutations. Hum Mol Genet. 2013;22(18):3667–79. doi: 10.1093/hmg/ddt21623669347; PubMed Central PMCID: PMCPMC3749859.
57. Kochs G, Garcia-Sastre A, Martinez-Sobrido L, Multiple anti-interferon actions of the influenza A virus NS1 protein. J Virol. 2007;81(13):7011–21. doi: 10.1128/JVI.02581-0617442719; PubMed Central PMCID: PMCPMC1933316.
58. Nistal-Villan E, Gack MU, Martinez-Delgado G, Maharaj NP, Inn KS, Yang H, et al. Negative role of RIG-I serine 8 phosphorylation in the regulation of interferon-beta production. J Biol Chem. 2010;285(26):20252–61.
59. Yun T, Park A, Hill TE, Pernet O, Beaty SM, Juelich TL, et al. Efficient reverse genetics reveals genetic determinants of budding and fusogenic differences between Nipah and Hendra viruses and enables real-time monitoring of viral spread in small animal models of henipavirus infection. J Virol. 2015;89(2):1242–53. doi: 10.1128/JVI.02583-1425392218; PubMed Central PMCID: PMCPMC4300668.